Volume 21 Issue 11
Nov.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(11): 1834-1836
LI Xueling, WANG Luyao, ZUO Zhengcai, WANG Guihong. Efficacy of sildenafil citrate in treating pulmonary hypertension associated with connective tissue disease[J]. Chinese Journal of General Practice, 2023, 21(11): 1834-1836. doi: 10.16766/j.cnki.issn.1674-4152.003236
Citation: LI Xueling, WANG Luyao, ZUO Zhengcai, WANG Guihong. Efficacy of sildenafil citrate in treating pulmonary hypertension associated with connective tissue disease[J]. Chinese Journal of General Practice, 2023, 21(11): 1834-1836. doi: 10.16766/j.cnki.issn.1674-4152.003236
shu

Efficacy of sildenafil citrate in treating pulmonary hypertension associated with connective tissue disease

doi: 10.16766/j.cnki.issn.1674-4152.003236

  • Department of Rheumatism Immunology, Anqing Medical Center of Anhui Medical University (Anqing Municipal Hospital), Anqing, Anhui 246003, China

Funds:

 82273710

  • Received Date: 2023-03-25
    Available Online: 2024-01-13
    Abstract
  •   Objective  To investigate the changes of hemodynamic parameters and exercise ability in patients with pulmonary hypertension associated with connective tissue disease (CTD-PAH) before and after oral sildenafil citrate treatment, in order to evaluate its clinical efficacy.  Methods  Twenty-six CTD-PAH patients who visited the Outpatient and Ward of Rheumatology and Immunology Department of Anqing Medical Center of Anhui Medical University (Anqing Municipal Hospital) from January 1, 2022 to March 1, 2023 were selected as research objects. Enrolled patients were given oral sildenafil citrate for 12 weeks. The changes of 6-min walking test (6MWT), pulmonary artery systolic blood pressure (PASP) and N-terminal B-type natriuretic peptide (NT-proBNP) before and after treatment were observed. The changes of laboratory indexes, blood pressure and heart rate were followed up.  Results  (1) After treatment, the 6MWT distance of patients increased from (271.231±34.386) m to (423.310±44.909) m. PASP decreased from (103.080±8.309) mmHg (1 mmHg=0.133 kPa) to (69.058±4.995) mmHg. Plasma NT-proBNP decreased from (1 983.650±46.175) pg/mL to (937.458±203.686) pg/mL. The three indexes were statistically significant before and after treatment (all P < 0.05). (2) Adverse reactions: after follow-up observation, there were no significant differences in blood pressure, heart rate, liver and kidney function before and after treatment (all P>0.05).  Conclusion  Sildenafil citrate treatment in patients with CTD-PAH can significantly improve the physical fitness of patients, significantly reduce SPAP, improve cardiac function and have no significant adverse effects on blood pressure, heart rate, liver and kidney function, with good safety.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    ZHAO J L, WANG Q, WANG Q, et al. 2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension[J]. Rheumatol Immunol Res, 2021, 2(2): 63-78. doi: 10.2478/rir-2021-0010
    [2]
    CHEN H A, HSU T C, YANG S C, et al. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study[J]. Arthritis Res Ther, 2019, 21(1): 82. doi: 10.1186/s13075-019-1868-0
    [3]
    PAN J, LEI L, ZHAO C, et al. Clinical characteristics and survival of patients with three major connective tissue diseases associated with pulmonary hypertension: a study from China[J]. Exp Ther Med, 2021, 22(3): 925. doi: 10.3892/etm.2021.10357
    [4]
    LIM Y H, LOW T T, CHAN S P, et al. Pulmonary arterial hypertension in a multi-ethnic Asian population: characteristics, survival and mortality predictors from a 14-year follow-up study[J]. Respirology, 2019, 24(2): 162-170. doi: 10.1111/resp.13392
    [5]
    POPE J E, DENTON C P, JOHNSON S R, et al. State-of-the-art evidence in the treatment of systemic sclerosis[J]. Nat Rev Rheumatol, 2023, 19(4): 212-226. doi: 10.1038/s41584-023-00909-5
    [6]
    DEPASCALE R, DEL FRATE G, GASPAROTTO M, et al. Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review[J]. Ther Adv Musculoskelet Dis, 2021, 13: 1759720X211040696. DOI: 10.1177/1759720X211040696.
    [7]
    LEMMERS J M, FRETHEIM H, KNAAPEN H K, et al. Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series[J]. J Scleroderma Relat Disord, 2020, 5(3): NP7-NP11. DOI: 10.1177/2397198320916082.
    [8]
    LI M T, WANG Y H, ZHAO J L, et al. Chinese SLE Treatment and Research group (CSTAR) registry 2009—2019: major clinical characteristics of Chinese patients with systemic lupus erythematosus[J]. Rheumatol Immunol Res, 2021, 2(1): 43-47. doi: 10.2478/rir-2021-0001
    [9]
    GIORDANO N, CORALLO C, CHIRICO C, et al. Pulmonary arterial hypertension in systemic sclerosis: diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines[J]. J Scleroderma Relat Disord, 2019, 4(1): 35-42. doi: 10.1177/2397198318808998
    [10]
    朱玲娴, 赵荫环, 张蕊, 等. 系统性硬化症发生肺动脉高压的独立危险因素分析[J]. 风湿病与关节炎, 2023, 12(1): 14-18.

    ZHU L X, ZHAO Y H, ZHANG R, et al. Independent risk factors of pulmonary hypertention in systemic sclerosis[J]. Rheumatism And Arthritis, 2023, 12(1): 14-18.
    [11]
    谢长好, 李志军. 系统性红斑狼疮的诊断与治疗[J]. 中华全科医学, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8

    XIE C H, LI Z J. Diagnosis and treatment of systemic lupus erythematosus[J]. Chinese Journal of General Practice, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8
    [12]
    QIAN J Y, DING Y F, YANG X Y, et al. The diagnostic and prognostic value of growth differentiation factor-15 in systemic lupus erythematosus-associated pulmonary arterial hypertension[J]. Pulm Circ, 2023, 13: e12195. DOI: 10.1002/pul2.12195.
    [13]
    WEATHERALD J, HUMBERT M. PDE5 to keep them alive: the use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease[J]. Respirology, 2023, 28(3): 212-214. doi: 10.1111/resp.14399
    [14]
    王建军, 吕群, 龚玲, 等. 原发性干燥综合征合并间质性肺病患者临床与影像特点分析[J]. 中华全科医学, 2019, 17(8): 1275-1278. doi: 10.16766/j.cnki.issn.1674-4152.000920

    WANG J J, LYU Q, GONG L, et al. Analysis of clinical and imaging features of primary Sjogren ' s syndrome complicated with interstitial lung disease[J]. Chinese Journal of General Practice, 2019, 17(8): 1275-1278. doi: 10.16766/j.cnki.issn.1674-4152.000920
    [15]
    SANGANI R A, LUI J K, GILLMEYER K R, et al. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: contribution from pulmonary hypertension and interstitial lung disease severity[J]. Pulm Circ, 2022, 12(4): e12117. DOI: 10.1002/pul2.12117.
    [16]
    VILELA V S, DIAS M M, SALGADO Â A, et al. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up[J]. BMC Pulm Med, 2021, 21(1): 251. doi: 10.1186/s12890-021-01618-z
    [17]
    朱轩池, 刘秀梅. 系统性硬化症相关肺动脉高压的治疗进展[J]. 临床与病理杂志, 2021, 41(7): 1696-1702.

    ZHU X C, LIU X M. Progress in the treatment of systemic sclerosis-associated pulmonary arterial hypertention[J]. J Clin Pathol Res, 2021, 41(7): 1696-1702.
    [18]
    VONK M C, VANDECASTEELE E, VAN DIJK A P. Pulmonary hypertension in connective tissue diseases, new evidence and challenges[J]. Eur J Clin Invest, 2020, 51(4): e13453. DOI: 10.1111/eci.13453.
    [19]
    TRAN-DUY A, MORRISROE K, CLARKE P, et al. Cost-effectiveness of combination therapy for patients with systemic sclerosis-related pulmonary arterial hypertention[J]. J Am Heart Assoc, 2021, 10(7): e015816. DOI: 10.1161/JAHA.119.015816.
    [20]
    AHMED W S, GEETHAKUMARI A M, BISWAS K H. Phosphodiesterase 5(PDE5): structure-function regulation and therapeutic application of inhibitors[J]. Biomed Pharmacother, 2021, 134: 111128. DOI: 10.1016/j.biopha.2020.111128.
    [21]
    RUARO B, CONFALONIERI M, SALTON F, et al. The relationship between pulmonary damage and peripheral vascular manifestations in systemic sclerosis patients[J]. Pharmaceuticals(Basel), 2021, 14(5): 403. doi: 10.3390/ph14050403
    [22]
    刘玉芳, 石磊. 波生坦治疗结缔组织病相关肺动脉高压临床疗效观察及安全性分析[J]. 中国药物与临床, 2019, 19(6): 867-869.

    LIU Y F, SHI L. Clinical efficacy and safety of bosentan in treatment of connective tissue disease associated pulmonary arterial hypertention[J]. Chinese Remedies &Clinics, 2019, 19(6): 867-869.
    [23]
    WANG Q, QIAN J Y, LI M T, et al. Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study[J]. Ther Adv Chronic dis, 2022, 13: 20406223221112528. DOI: 10.1177/20406223221112528.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (230) PDF downloads(14) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return